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function of apolipoprotein O in HepG2 cell line
Chen-Lu Wu, Shui-Ping Zhao* and Bi-Lian Yu*Abstract
Background: Apolipoprotein O (apoO) is a new member of the apolipoprotein family. However, data on its
physiological functions are limited and inconsistent. Using a microarray expression analysis, this study explored the
function of apoO in liver cells.
Methods: HepG2 cells were treated either with oleic acid or tumor necrosis factor-α for 24 h. mRNA and protein
expression of apoO were assessed by quantitative real-time PCR (qRT-PCR) and Western blot respectively. An
efficient lentiviral siRNA vector targeting the human apoO gene was designed and constructed. The gene
expression profile of HepG2 human hepatocellular carcinoma cells transfected with the apoO silencing vector was
investigated using a whole-genome oligonucleotide microarray. The expression levels of some altered genes were
validated using qRT-PCR.
Results: ApoO expression in HepG2 cells was dramatically affected by lipid and inflammatory stimuli. A total of 282
differentially expressed genes in apoO-silenced HepG2 cells were identified by microarray analysis. These genes
included those participating in fatty acid metabolism, such as ACSL4, RGS16, CROT and CYP4F11, and genes
participating in the inflammatory response, such as NFKBIZ, TNFSF15, USP2, IL-17, CCL23, NOTCH2, APH-1B and N2N.
The gene Uncoupling protein 2 (UCP2), which is involved in both these metabolic pathways, demonstrated
significant changes in mRNA level after transfection.
Conclusions: It is likely that apoO participates in fatty acid metabolism and the inflammatory response in HepG2
cells, and UCP2 may act as a mediator between lipid metabolism and inflammation in apoO-silenced HepG2 cells.
Keywords: Apolipoprotein O, Inflammation, Lipid metabolism, Fatty acidsBackground
Apolipoprotein O (apoO) is a novel apolipoprotein
which was first discovered in 2006 [1], but to date, rela-
tively little is known about its physiological functions.
An in vitro study displayed that purified recombinant
apoO facilitated cholesterol efflux from J774 mouse
macrophage cells [1]. However, this effect has not been
replicated in vivo [2]. Recently, we found that apoO
levels were increased in acute coronary syndrome pa-
tients and positively associated with the inflammatory
marker high-sensitive C-reactive protein (hsCRP), sug-
gesting a potential role as an inflammatory predictor [3].
Therefore, apoO seems to be implicated in lipid metab-
olism and inflammation.* Correspondence: zhaosp@medmail.com; bilian-yu@hotmail.com
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stated.Here, the effects of lipid and inflammatory stimuli on
apoO were investigated. A microarray assay was used to
identify genes that are differentially expressed in apoO-
silenced HepG2 cells. This study could enable the func-
tion of apoO in liver cells to be elucidated.Results
Oleic acid increased the expression of apoO in HepG2
cells
We determined if a lipid stimulus would influence the ex-
pression of apoO in HepG2 cells. Figure 1 shows apoO
mRNA and protein levels in cells treated with oleic acid
(OA) compared with the levels in control cells. As ex-
pected, incubation of HepG2 cells with 1 mmol/L OA for
24 h induced a 4-fold increase in apoO mRNA (P < 0.01)
and a 2-fold increase in apoO protein expression (P < 0.05).. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited. The Creative Commons Public Domain Dedication
ain/zero/1.0/) applies to the data made available in this article, unless otherwise
Figure 1 ApoO mRNA and protein changes in HepG2 cells pretreated with 1 mmol/L OA for 24 h. A. The relative levels of apoO mRNA
were analyzed by qRT-PCR. Data shown are the mean ± S.E.M from experiments repeated in triplicate with three samples per treatment. **p <
0.01 vs. control. B. The relative levels of apoO protein were analyzed by Western blot analysis. β-actin served as a loading control. These experi-
ments were performed three times, and the results of the densitometric analysis and one representative image are shown. * p < 0.05 vs. control.
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in HepG2 cells
To explore the effect of inflammatory stimulus on
the expression of apoO, we detected apoO mRNA
and protein expression changes in HepG2 cells pre-
treated for 24 h with 100 ng/mL tumor necrosis
factor-α (TNF-α). Quantitative real-time PCR (qRT-
PCR) demonstrated that TNF-α treatment led to a
3-fold up-regulation of apoO mRNA expression
(P < 0.01; Figure 2A). ApoO protein levels were ap-
proximately 2.5-fold higher after incubation (P < 0.05;
Figure 2B).Figure 2 Levels of ApoO mRNA and protein in HepG2 cells pretreated
mRNA were analyzed by qRT-PCR. Data shown are the mean ± S.E.M from
**p < 0.01 vs. control. B. The relative levels of apoO protein were analyzed
periments were performed three times, and the results of the densitometri
vs. control.LV2 was identified as an efficient vector capable of
silencing apoO
Using GenBank information for the human apoO gene,
three interfering sequences and a negative control sequence
were designed and designated as LV1, LV2, LV3 and NC.
PCR identification and DNA sequencing demonstrated the
correct insertion of the oligonucleotides into the vectors.
qRT-PCR and Western blot analysis confirmed that LV2
could significantly inhibit apoO expression in HeLa cells
when the multiplicity of infection (MOI) =10 (P < 0.001;
Figure 3), whereas LV1 and LV3 had no apparent effect
(P > 0.05).with 100 ng/mL TNF-α for 24 h. A. The relative levels of apoO
experiments repeated in triplicate with three samples per treatment.
by Western blot analysis. β-actin served as a loading control. These ex-
c analysis and one representative image are shown. * p < 0.05
Figure 3 Screening for an efficient lentiviral vector capable of silencing apoO expression. A. HeLa cells observed by fluorescence
microscopy 3 days after infection (magnification, ×200). B. The relative levels of apoO mRNA transcripts were analyzed by qRT-PCR. Data shown
are means ± S.E.M from three independent experiments. **p < 0.001 vs. negative controls (NC). C. Effects of apoO silencing were measured using
Western blot. NC: cells infected with negative control RNAi; LV1: cells infected with apoO-specific RNAi-1; LV2: cells infected with apoO-specific
RNAi-2; LV3: cells infected with apoO-specific RNAi-3. β-actin served as a loading control. These experiments were performed three times, and the
results of the densitometric analysis and one representative image are shown. **p < 0.001 vs. negative control (NC).
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apoO expression in HepG2 cells
Three days after infection, HepG2 cells were visualized
using fluorescence microscopy. A comparison between
the bright-field and fluorescent images showed that most
cells had green fluorescent signals when MOI = 20
(Figure 4A). The levels of apoO mRNA and protein were
analyzed 5 days and 7 days after transfection, respect-
ively. The level of apoO mRNA in cells transfected with
apoO-specific-RNAi lentivirus was decreased by ap-
proximately 78% (P < 0.01) compared to the control cells
(Figure 4B). ApoO protein was also down-regulated by
approximately 80% in cells with the apoO-specific RNAi
(P < 0.01; Figure 4C).
Differentially expressed genes in apoO-silenced HepG2
cells
Comparison of mRNA levels between negative control
cells (NC) and apoO-silenced cells (LV) revealed that
many genes were differentially expressed. In summary,
the expression of 282 genes was significantly altered: 192
genes were up-regulated and 90 genes were down-
regulated (≥2 fold up- or down-regulated; Figure 5A,
n = 6, P < 0.05). The expression of the FBXL21 gene,
which showed the strongest up-regulation, was increased
by 5.142-fold, whereas the expression of the HRB gene,
which showed the strongest down-regulation, was de-
creased by 6.485-fold. Of the genes with alteredexpression patterns, 18 were involved in lipid metabol-
ism (Table 1) and 16 were involved in inflammation
(Table 2). Moreover, gene ontology (GO) analysis identi-
fied involvement of the differentially expressed genes in
several cellular biological processes, such as 1) glyceroli-
pid metabolism, 2) glycerophospholipid metabolism, 3)
sphingolipid catabolism, 4) membrane lipid catabolism,
5) cellular lipid metabolism, 6) phospholipid metabolism,
7) phosphatidylinositol metabolism, 8) the Notch signal-
ing pathway, 9) steroid catabolism, 10) phospholipid
biosynthetic processes, 11) glycerophospholipid biosyn-
thetic processes, 12) sphingolipid metabolism, 13) re-
sponse to superoxide, and 14) response to oxygen
radicals (Table 3).
Confirmation of microarray results by qRT-PCR
To validate the microarray results, we assessed the ex-
pression of a subset of genes with qRT-PCR, including:
NFKBIZ, FBXL21, HRB, NOTCH2, UCP2, ACSL4 and
CEL. The high concordance of expression levels found
between the microarray analysis and the qRT-PCR re-
sults for these genes confirmed that the microarray data
were reliable (Figure 5B).
Discussion
The liver is the most metabolically active organ in the hu-
man body and is responsible for many vital functions, in-
cluding lipid metabolism. Triglycerides (TGs) accumulate
Figure 4 Down-regulation of apoO expression in HepG2 cells using lentivirus-mediated RNAi. A. HepG2 cells were observed by
fluorescence microscopy 3 days after infection (magnification, ×200). B. The relative levels of apoO mRNA were analyzed by qRT-PCR. Data shown
are the means ± S.E.M of experiments repeated three times with triplicate samples per treatment. **p < 0.01 vs. NC; ## p < 0.01 vs. control. C. Ef-
fects of apoO silencing were measured using Western blots. β-actin served as a loading control. These experiments were performed three times,
and the results of the densitometric analysis and one representative image are shown. ** p < 0.01 vs. NC; ## p < 0.01 vs. control.
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and synthesis of TG can produce FAs and specific toxic
lipid intermediates that activate intracellular inflammatory
pathways. FA oxidation provides a major source of reactive
oxygen species (ROS). During the process of hydrolysis, TG
expands the availability of FA to metabolic pathways, such
as peroxidation; increases ROS; and, subsequently, in-
creases levels of oxidative stress. Oxidative stress results inFigure 5 Differentially expressed genes and verification. A. Hierarchica
group vs. the interference group. The rows show individual genes, while th
expression and blue denotes low expression. B. Comparison of the express
group and the apoO-silenced group by microarray analysis and qRT-PCR. A
normalized using GAPDH as an endogenous control for RNA input. Fold-ch
shown as means ± S.E.M. (n = 6 for each group).the activation of several key pro-inflammatory signaling
pathways, including the nuclear factor-kappa B (NF-κB)
pathway [4]. Conversely, although TG synthesis decreases
cellular FA concentrations, this process also generates other
potentially toxic lipid intermediates [5]. Therefore, dysfunc-
tional FA metabolism influences the cellular inflammatory
state and is involved in the pathogenesis of liver disorders,
such as non-alcoholic fatty liver disease (NAFLD) [6].l clustering of differentially expressed genes in the negative control
e columns show individual tissue samples. Red denotes high
ion levels of genes as fold-changes between the negative control
ssays were performed from each RNA sample in triplicate. Data were
anges for these microRNAs from the microarray and qRT-PCR are
Table 1 Differential expressed genes related to lipid metabolism
Gene name NCBIGene ID Fold change FDR P value Description
CEL BC042510 2.383↑ 0.999 0.030 Carboxyl ester lipase(bile salt-stimulated lipase)
CROT BC051874 2.271↓ 0.999 0.037 Carnitine O-octanoyltransferase
AGPAT2 NM_006412 2.025↓ 0.999 0.015 1-acylglycerol-3-phosphate O-acyltransferase 2 (lysophospha-tidic acid acyltransferase, beta)
CYP4F11 NM_021187 2.490↓ 0.999 0.014 Cytochrome P450, family 4, subfamily F, polypeptide 11
PI4KII NM_018425 2.140↓ 0.999 0.046 Phosphatidylinositol 4-kinase type II
PIP5KL1 NM_173492 2.171↓ 0.999 0.017 Phosphatidylinositol-4-phosphate 5-kinase-like 1
G6PC2 BC104778 2.091↑ 0.999 0.014 Glucose-6-phosphatase,catalytic,2
SERINC5 BC101281 2.586↑ 0.999 0.018 Serine incorporator 5
SMPDL3B NM_001009568 2.000↑ 0.999 0.037 Sphingomyelin phosphodiesterase, acid-like 3B
ACSL4 NM_004458 2.803↑ 0.999 0.017 Acyl-CoA synthetase long-chain family member 4
RBP1 NM_002899 2.031↑ 0.999 0.044 Retinol binding protein 1, cellular
LASS1 NM_198207 2.018↑ 0.999 0.014 LAG1 longevity assurance homolog 1 (S. cerevisiae)
HSD17B6 NM_003725 2.051↓ 0.999 0.033 Hydroxysteroid(17-beta) dehydrogenase 6
PIGW BC033540 2.201↑ 0.999 0.016 Phosphatidylinositol glycan, class W
RGS16 NM_002928 2.936↑ 0.999 0.023 Regulator of G-protein signalling 16
KLF5 NM_001730 2.192↓ 0.999 0.016 Kruppel-like factor 5 (intestinal)
UCP2 NM_003355 2.248↓ 0.999 0.028 Uncoupling protein 2 (mitochondrial, proton carrier)
UCP3 NM_003356 2.420↓ 0.999 0.006 Uncoupling protein 3 (mitochondrial, proton carrier)






















Table 2 Differential expressed genes related to inflammation
Gene name NCBIGene ID Fold change FDR P value Description
APH-1B AB189172 2.372↓ 0.999 0.040 Anterior pharynx defective 1 homolog B (C. elegans)
NFAT5 AJ243299 2.249↑ 0.999 0.040 Nuclear factor of activated T-cells 5, tonicity-responsive
SLC37A2 AK074207 2.936↑ 0.999 0.023 Solute carrier family 37 (glycerol-3-phosphate transporter), member 2
IL17A BC066251 2.097↑ 0.999 0.004 Interleukin 17 (cytotoxic T-lymphocyte-associated serine esterase 8)
LILRB2 NM_005874 2.014↑ 0.999 0.046 Leukocyte immunoglobulin-like receptor, subfamily B (with TM and ITIM domains), member 2
RASGRF2 NM_006909 2.091↑ 0.999 0.048 Ras protein-specific guanine nucleotide-releasing factor 2
NFKBIZ NM_001005474 2.302↓ 0.999 0.012 Nuclear factor of kappa light polypeptide gene enhancer in B-cells inhibitor, zeta
CD160 NM_007053 2.401↑ 0.999 0.015 CD160 molecule
N2N NM_203458 2.144↑ 0.999 0.005 Notch homolog 2 (Drosophila) N-terminal like
NOTCH2 BC071562 2.082↓ 0.999 0.008 Notch homolog 2 (Drosophila)
TNFSF15 BC074941 2.022↑ 0.999 0.045 Tumor necrosis factor (ligand) superfamily, member 15
CCL23 NM_005064 2.570↑ 0.999 0.017 Chemokine (C-C motif) ligand 23
DTL BC033540 2.356↑ 0.999 0.021 Denticleless homolog (Drosophila)
USP2 NM_171997 2.088↑ 0.999 0.019 Ubiquitin specific peptidase 2
UCP2 NM_003355 2.248↓ 0.999 0.028 Uncoupling protein 2 (mitochondrial, proton carrier)
UCP3 NM_003356 2.420↓ 0.999 0.006 Uncoupling protein 3 (mitochondrial, proton carrier)






















Table 3 GO analysis of the differentially expressed genes
Gene ontology Fold enrichment P value Genes








Cellular lipid metabolic process 1.963 0.0198 ACSL4//CROT//UCP3//CEL//AGPAT2//SERINC5//PI4KII//SMPDL3B//PIGW//
RBP1//PIP5KL1//LASS1




Notch signaling pathway 4.679 0.0263 NOTCH2NL//NOTCH2//APH1B







Sphingolipid metabolic process 3.667 0.0486 SMPDL3B//LASS1//CEL
Response to superoxide 18.095 0.0052 UCP2//UCP3
Response to oxygen radical 16.45 0.0063 UCP2//UCP3
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HepG2 cells to OA as well as TNF-α can result in the
increased expression of apoO. To account for this
phenomenon, we examined gene expression in apoO-
silenced HepG2 cells with the use of microarrays. Ac-
cording to our microarray data, silencing apoO in
HepG2 cells leads to the differential expression of sev-
eral important lipid signaling and inflammation genes.
FA metabolism
In comparison with the negative control cells, ACSL4
was up-regulated in apoO-silenced HepG2 cells. ACSL4
encodes an isoform of the long-chain acyl-CoA synthe-
tase (ACSL), which catalyzes acyl-CoA synthesis by con-
verting long-chain FA to acyl-CoA. African-American
NAFLD patients over-express ACSL4 [7]; ACSL4 mRNA
levels have been positively associated with liver TG con-
centrations [8]. Thus, increased ACSL4 expression could
indicate an up-regulation of TG synthesis.
Mitochondria are the major site of FA oxidation.
RGS16 encodes a protein which inhibits G protein-
coupled receptor (GPCR)-stimulated FA oxidation in
liver mitochondria [9]. Its expression increased after
transfection. CROT and CYP4F11 encode two key FA
oxidation enzymes, respectively. In the peroxisome, stor-
age of medium chain acyls slows down peroxisomal beta
oxidation. When CROT activity increases, the level of
medium chain acyls decreases as they are converted into
acyl-carnitines [10]. In the microsome, another FA oxi-
dation site, CYP4F11 is the predominant catalyst of FAomega hydroxylation [11]. Within this context, silencing
of apoO with altered RGS16, CROT and CYP4F11 ex-
pression would modulate not only FA oxidation rates
but also cellular TG content.
Inflammatory responses
The NF-κB protein family includes transcription factors
that regulate crucial cellular processes, such as the inflam-
mation response. NFKBIZ encodes a novel member of the
IκB family, IκB zeta. IκB zeta associates with both the p65
and p50 subunits of NF-κB and inhibits the transcriptional
activity and DNA binding of NF-κB [12]. USP2 is a
ubiquitin-specific protease which is required for the phos-
phorylation of IκB and functions as an additional positive
regulator of TNF-α-induced NF-κB signaling [13]. The pro-
tein encoded by TNFSF15 gene is a cytokine that belongs
to the tumor necrosis factor ligand family and is capable of
activating NF-κB [14]. In addition, the two cytokines IL-17
and CCL23 may induce inflammatory gene expression by
interaction with the NF-κB pathway [15,16]. As apoO silen-
cing in HepG2 cells resulted in down-regulation of NFKBIZ
and up-regulation of the pro-inflammatory molecules men-
tioned above, it is possible that apoO may exert anti-
inflammatory effects through suppressing NF-κB pathway.
Notch signaling is involved in the inflammatory re-
sponse [17]. There is complex crosstalk between the
Notch 2 and NF-κB pathways as both pathways can
exert either synergistic or antagonistic effects depending
on different cellular contexts [18-20]. APH-1 is one of
the four components of γ-secretase complex, which is
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main (NICD) into the cytoplasm. These subunits are suf-
ficient and required for γ-secretase activity [21]. The
product of N2N gene is homologous to Notch 2. In vitro,
N2N repressed the transcriptional activity of the Notch
2 protein in a dose-dependent manner [22]. Our micro-
array data showed that activation of NF-κB pathway was
accompanied by impaired expression of Notch2, APH-1B
and enhanced expression of N2N, suggesting the antag-
onistic effect between the NF-κB and Notch 2 signaling
pathways in apoO-silenced HepG2 cells.
Uncoupling proteins
Uncoupling protein (UCP) 2 and UCP3 are members of
a mitochondrial carrier protein superfamily that controls
the level of respiration coupling. The UCP2 and UCP3
genes are located together in a gene cluster, but the pat-
tern of their expression is very different. UCP3 is pri-
marily expressed in skeletal muscle tissue, whereas
UCP2 is expressed widely. Although these two uncoup-
ling proteins are thought to have similar physiological
functions [23], the changes of UCP2 expression levels in
liver cells may be more significant. UCP2 can dissipate
the proton gradient across the mitochondrial inner
membrane to prevent the proton-motive force from be-
coming excessive, thus limiting mitochondrial ROS pro-
duction. It acts as a sensor for mitochondrial oxidative
stress and protects against oxidative damage by control-
ling the production of ROS [24]. UCP2 is also implicated
in fat oxidation and the regulation of fat content. It
functions as a metabolic switch that is involved in the
choice of substrate oxidized by mitochondria which pro-
motes FA metabolism over glucose utilization [25]. It
could be speculated that reduction of UCP2 expression
in apoO-silenced HepG2 cells would lead to mitochon-
drial dysfunction accompanied by elevated ROS produc-
tion and oxidative stress in hepatocytes. Subsequently,
mitochondria might regulate the generation of ROS by
altering the activity levels of enzymes that can affect FA
oxidation. Therefore, reduction of UCP2 provides a pos-
sible mechanism in which FA metabolism and ROS-
induced inflammatory responses can be simultaneously
modulated in HepG2 cells after the silencing of apoO.
Limitations
Some limitations of this study should be considered.
Firstly, although the HepG2 hepatoma cell line is fre-
quently used to study apolipoprotein metabolism, they
are not the gold standard model for the study of the na-
tive liver. Therefore, gene expression changes related to
apoO in our study may not reflect those that occur in
liver in vivo. Secondly, we have only reported the result
of an experiment that illustrated that apoO expression
was dramatically affected by OA and TNF-α, butchanges in inflammation and lipid metabolism genes in
apoO-silenced HepG2 cells pretreated either with OA or
TNF-α were not explored. Hence, the exact mechanisms
involved in apoO-dependent changes in gene expression
have yet to be elucidated. In addition, apoO, besides be-
ing secreted, could reside within cells where it is
expressed [1]. It may affect hepatocytes as a paracrine
and/or autocrine factor, or even as an intracellular pro-
tein. This study did not differentiate whether changes of
gene expression are due to the secreted apoO, or due to
the intracellular apoO.
Conclusions
Our findings provide significant data to propose a role
for apoO in HepG2 cells. Using a whole-genome micro-
array analysis, we have demonstrated that apoO may
play an active role in FA metabolism in HepG2 cells by
inhibiting TG synthesis and promoting FA oxidation.
Furthermore, it is possible that apoO could suppress
hepatic inflammation via the NF-κB and Notch 2 signal-
ing pathways. UCP2 provides an underlying connection
between the changes in expression levels of lipid metab-




HepG2 cells and HeLa cells (originally obtained from
the American Type Culture Collection, ATCC) were
maintained in Dulbecco’s modified Eagle’s medium
(DMEM; Invitrogen, Carlsbad, CA, USA) at 37°C under
5% CO2, supplemented with 10% fetal bovine serum
(FBS; Invitrogen, Carlsbad, CA, USA).
For experimental incubations, cells were washed once
in serum-free medium for 2 h. The medium was then re-
placed or cells were incubated with this medium with
the addition of 1 mmol/L OA (Sigma, St. Louis, MO,
USA) or 100 ng/mL TNF-α (Sigma, St. Louis, MO, USA)
for 24 h.
RNA isolation and qRT-PCR analysis
Total cellular RNA was isolated using Trizol reagent
(Invitrogen, Carlsbad, CA, USA) according to the manu-
facturer’s instructions, and was quantified using a Nano-
Drop Spectrophotometer (Nanodrop, Rockland, DE,
USA). cDNA was synthesized using a cDNA Synthesis
Kit (Fermentas, Burlington, Ontario, Canada). qRT-PCR
was performed with the SYBR Green Master Mix re-
agent (ABI, Foster City, CA, USA) in an ABI 7300 RT-
PCR apparatus according to the manufacturer’s protocol.
For each gene, qRT-PCR was run on each sample in
triplicate. Transcript levels were normalized using
GAPDH RNA quantification. The results of the qRT-
PCR were statistically analyzed with SigmaStat software
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tion tests are listed in Table 4.
Protein extractions and Western blots
Extraction of cellular protein and Western blot analyses
were carried out as previously described [26]. The pro-
tein bands were detected using ECL detection reagents
(Pierce Biotechnology, Rockford, IL, USA) and quanti-
fied by densitometric analysis.
Construction of the lentiviral vectors
Complementary DNAs containing both the sense and
antisense oligo DNAs of the targeting sequences were
synthesized, and were annealed into double-stranded
DNA. The DNA products obtained were cloned into the
lentiviral pFU-GW-iRNA vector (GeneChem, Shanghai,
China) to construct the experimental vectors, which
were then identified by PCR and DNA sequencing. The
successfully constructed vectors were packaged using a
packaging plasmid mix. The virus titers were tested.
HeLa cells were infected by the lentivirus constructs,
and the efficiencies of apoO interference were identified
by qRT-PCR and Western blot.
SiRNA silencing
The day before transfection, cells were seeded into 6-
well culture plates at a density of 105 cells per well. On
the day of transfection, they were infected with the lenti-
viral constructs (either the apoO-silencing vector or theTable 4 Real-time PCR primers used in the validation and
stimulation tests
Primer Sequence
NFKBIZ F: 5′- GTTGTCTGATGGACCTGC −3′
R: 5′- CTGTTTGGGTTCATTGAG −3′
FBXL21 F: 5′- TAAGTCCACTCATCCTGATCT −3′
R: 5′- CAAAATGAGACTCCGACACA −3′
HRB F: 5′- CAAAGAGGACAATCCCAGAG- 3′
R: 5′- GATCAGGTCCAGGGTTGC −3′
NOTCH2 F: 5′- CCCAATGGGCAAGAAGTCTA −3′
R: 5′- CACAATGTGGTGGTGGGATA −3′
UCP2 F: 5′- CGGTTACAGATCCAAGGA −3′
R: 5′- ACCAGCCCATTGTAGAGG −3′
ACSL4 F: 5′- TTGCCATCTTCTGTGAGA −3′
R: 5′- GGTAATCAGATAGGAAGCC −3′
CEL F: 5′- TATGATCTGGATCTATGGAGG −3′
R: 5′- CGACACGGTAGTTGAAGGT −3′
APOO F: 5′- GGTGTCAGGAAACGTACTCCC −3′
R: 5′- AACCCCCATTGAACCAAACTT −3′
GAPDH F: 5′- GGAAGGTGAAGGTCGGAGTC −3′
R: 5′- GCTCCTGGAAGATGGTGATGG −3′negative control vector) at a favorable MOI. At 12 h
after transfection, the medium was replaced. Cells were
collected for RNA isolation and qRT-PCR analysis 5 days
after transfection. Seven days after transfection, cellular
proteins were extracted and Western blot analyses were
conducted.
Microarray analysis
About 5 μg total RNA from each sample was used for label-
ing and array hybridization as follows: 1) reverse transcrip-
tion was carried out using the Invitrogen Superscript ds-
cDNA Synthesis Kit (Invitrogen, Carlsbad, CA, USA); 2)
ds-cDNA was labelled using the NimbleGen one-color
DNA Labeling Kit (Roche NimbleGen, Madison, WI,
USA); 3) array hybridization was performed using the
NimbleGen Hybridization System (Roche NimbleGen,
Madison, WI, USA), followed by washing with the Nimble-
Gen Wash Buffer Kit (Roche NimbleGen, Madison, WI,
USA); 4) array scanning was carried out using the Axon
GenePix 4000B Microarray Scanner (Molecular Devices
Corporation). The data files were imported into Agilent
GeneSpring Software (Agilent, version 11.5) for analysis.
The gene expression levels in cells transfected with the effi-
cient siRNA were normalized to that in cells transfected
with the negative control siRNA. The microarray experi-
ment was independently repeated in triplicate. Genes that
were differentially expressed were identified by filtering the
mean ratios of fold-changes from replicates using P-value
thresholds (fold change ≥ 2 and P < 0.05) based on a t-test
analysis. To determine the potential biological functions
and pathways of differentially expressed genes, GO and
pathway analyses were applied. Finally, Hierarchical Clus-
tering was performed to show distinguishable gene expres-
sion profiling among samples.
Statistical analysis
Data were depicted as means ± S.E.M. Statistical analyses
were performed using SPSS software (Version 16.0, SPSS
Inc., Chicago, IL, USA). Single comparisons were per-
formed using the unpaired Student’s t-test with a value
of p ≤ 0.05 considered as significant.
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